NVAX Financial Facts
Basic and diluted net loss per share: -0.24Interest expense: -3.51M
See Full Income Statement
Total assets: 459.63M
Total stockholders' equity: 49.78M
See Full Balance Sheet
Novavax, Inc. (NVAX) Earnings
|
Expand Research on NVAX
| Next EPS Date | 5/7/24 | EPS Growth Rate | +72.1% |
|---|---|---|---|
| Average EPS % Beat Rate | -43.3% | Revenue Growth Rate | +85.7% |
| Average % Move 1-Wk after EPS | -8.2% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 8/8/22 | Q222 | -$6.53 | $5.50 | -$12.03 | $186B | $1.02B |  |
 | | Details | |
| 11/8/22 | Q322 | -$2.15 | $1.63 | -$3.78 | $735M | $623.9M | |
| | Details | |
| 5/9/22 |  |
Q122 | $2.56 | $2.69 | -$0.13 | $704M | $845.2M | |
| | Details |
| 5/10/21 | |
Q121 | -$3.05 | -$3.60 | +$0.55 | $447.23M | $233.9M | N/A | | | Details |
| 8/8/23 | Q223 | $0.58 | -$1.52 | +$2.10 | $424.43M | $237.39M | = | | | Details | |
| 2/28/23 | Q422 | -$2.28 | -$1.19 | -$1.09 | $357M | $383.14M | = | | | Details | |
| 8/5/21 | |
Q221 | -$4.75 | -$3.63 | -$1.12 | $298M | $387.87M | N/A | | | Details |
| 2/28/24 | Q423 | -$1.44 | -$0.45 | -$0.99 | $291M | $321.97M | = | | | Details |
